Shanghai RAAS Blood Products (002252) Fundamentals 2026 — P/E 25.8x, Revenue Analysis | SniperIQ
Shanghai RAAS Blood Products (002252) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥34.2B, trading at ¥5.18 on the SHZ. This SniperIQ fundamentals page covers Shanghai RAAS Blood Products's valuation (P/E 25.8x, P/B 1.0x), profitability (net margin 19.4%), revenue (¥7.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shanghai RAAS Blood Products's market cap?
Shanghai RAAS Blood Products (002252) has a market capitalization of approximately ¥34.2B, trading at ¥5.18 on the SHZ. Market cap moves with the live share price.
What is Shanghai RAAS Blood Products's P/E ratio?
Shanghai RAAS Blood Products's trailing twelve-month P/E ratio is 25.8x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shanghai RAAS Blood Products?
Shanghai RAAS Blood Products runs a net profit margin of 19.4%, a gross margin of 35.9%, and an operating margin of 22.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shanghai RAAS Blood Products generate?
Shanghai RAAS Blood Products reported revenue of ¥7.3B for fiscal year 2025, with net income of ¥1.6B and earnings per share (EPS) of 0.24. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shanghai RAAS Blood Products pay a dividend?
Shanghai RAAS Blood Products offers a trailing dividend yield of about 0.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shanghai RAAS Blood Products financially healthy?
Shanghai RAAS Blood Products carries a debt-to-equity ratio of 0.12x and a current ratio of 3.73x, with a market beta of 0.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shanghai RAAS Blood Products a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shanghai RAAS Blood Products (002252) the key facts are: market cap ¥34.2B, P/E 25.8x, revenue ¥7.3B, 52-week range 4.18-7.26. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shanghai RAAS Blood Products's full fundamentals live
Get Shanghai RAAS Blood Products's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.